Menu
Home
About Us
About Noxopharm
Board of Directors
Management Team
Our Focus
ASX Announcements
Financial Reports
Corporate Governance
Company Constitution
Privacy Policy
Sustainability
Upcoming Events
Our Science
Our Science
About Veyonda®
Cancer
Septic Shock
Our Publications
Related Research
The Abscopal Response
STING
Noxopharm White Papers
Why is Noxopharm Different?
Our Programs
Four Pillars Oncology Program
DARRT
LuPIN
IONIC
CEP
NOXCOVID COVID-19 Clinical Trial
Drug Development Program
About Pharmorage
Patients
Investors
Contact Us
Contact Us
Partnering
Working at Noxopharm
Newsletter Email Alerts
ASX Announcements Email Alerts
Our Science
Home
>
Our Science
>
Our Publications
Our Science
About Veyonda®
Cancer
Septic Shock
Our Publications
Related Research
The Abscopal Response
STING
Noxopharm White Papers
Why is Noxopharm Different?
Our Publications
Filter by Year:
2020
2019
2018
2017
20-Nov-2017
NOX66 Plus Carboplatin - Phase 1 Signalling Study
13-Nov-2017
ENOX2 levels of patients receiving NOX66
13-Nov-2017
Idronoxil levels of patients receiving NOX66
13-Nov-2017
Trial Design: Safety of NOX66 in Combination with Palliative Dose Radiotherapy - A Phase 1 Dose Escalation Study
11-Sep-2017
Chemosensitization of Carboplatin by NOX66
Previous
1
2
